预约演示
更新于：2025-07-22
Montelukast sodium
孟鲁司特钠
更新于：2025-07-22
概要
基本信息
简介Montelukast sodium，商业名称为SINGULAIR®，是一种CysLT拮抗剂药物，用于治疗哮喘，运动诱发的支气管痉挛（EIB）和过敏性鼻炎。这种药物于1997年在墨西哥获得首次批准，并已广泛用于全球哮喘和过敏性鼻炎的管理。它的化学描述为[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸单钠盐，可提供片剂，咀嚼片和口服颗粒剂等剂型。 |
药物类型 小分子化药 |
别名 Montelukast、Montelukast sodium (JP17/USP)、Montelukast Sodium Oral Granules + [15] |
靶点 |
作用方式 拮抗剂 |
作用机制 CysLT拮抗剂(半胱氨酰白三烯受体拮抗剂) |
原研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-02-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H36ClNNaO3S |
InChIKeyZMFQNQCXWQXCFO-HKHDRNBDSA-N |
CAS号151767-02-1 |
关联
546
项与 孟鲁司特钠 相关的临床试验NCT03277170
Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
CTR20250351
评估受试制剂孟鲁司特钠咀嚼片（规格：5 mg）与参比制剂顺尔宁®（规格：5 mg）在健康成年参与者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
NCT05992311
Clinical Evaluation of Montelukast on Cognitive and Mood Dysfunction and Neuroinflammation in Veterans with Gulf War Illness (GWI)
100 项与 孟鲁司特钠 相关的临床结果
登录后查看更多信息
100 项与 孟鲁司特钠 相关的转化医学
登录后查看更多信息
100 项与 孟鲁司特钠 相关的专利（医药）
登录后查看更多信息
4,180
项与 孟鲁司特钠 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-08-01Oral Surgery Oral Medicine Oral Pathology Oral Radiology
A clinical evaluation of the efficacy of montelukast in alleviating postoperative nasal congestion after bimaxillary orthognathic surgery
Article
作者: Goharian, Rozhin Kafshdar ; Jafari, Mahdi ; Grillo, Ricardo ; Samieirad, Sahand
OBJECTIVE:
The aim of this study was to evaluate the effect of oral montelukast administration on postoperative nasal congestion following orthognathic surgery.
METHODS:
Patients who underwent bimaxillary orthognathic surgery were enrolled in this triple-blind clinical trial. Rhinomanometry testing was performed to assess postoperative nasal congestion. Each patient received a 10 mg tablet of montelukast 1 hour before surgery and daily for 1 week thereafter, in comparison to a placebo group. After 1 week, rhinomanometry testing was conducted for both groups to evaluate postoperative nasal congestion. For statistical analysis, the significance level was set at 5%, using paired and independent t tests.
RESULTS:
A total of 44 patients with an average age of 26.98 ± 4.78 years were included. The average postoperative nasal airflow during both inhalation and exhalation was significantly higher in the montelukast group (P < .001). Additionally, the mean postoperative nasal resistance during both inhalation and exhalation was significantly lower in the montelukast group (P < .001).
CONCLUSIONS:
Oral administration of montelukast appears to be effective in reducing nasal congestion following orthognathic surgery.
2025-08-01JOURNAL OF PSYCHIATRIC RESEARCH
Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database
Article
作者: Ju, Yaxin ; Tan, Li ; Su, Li ; Liu, Yuan
OBJECTIVE:
The K-12 population refers to individuals, primarily aged 6-17, from kindergarten through 12th grade. Drug-related suicidal ideation (SI) in the K-12 population is a major concern. This study aims to identify medications linked to increased SI risk in the K-12 population using the FDA Adverse Event Reporting System (FAERS) database.
METHODS:
We extracted cases of SI in individuals aged 6-17 years where medications were the primary suspect (PS) from the FAERS database, spanning from the first quarter of 2004 to the third quarter of 2023. We conducted descriptive analysis, disproportionality analysis, and subgroup analysis.
RESULTS:
Our analysis included 4,779 valid cases; 52.75 % were male and 45.66 % were female. The predominant age group was 15-17 years, accounting for 43.92 % of cases. The peak year for case reports was 2019. Montelukast was the most common drug. The four most common indications included attention deficit hyperactivity disorder, depression, acne, and asthma. Disproportionality analysis highlighted 21 drugs as potentially associated with increased SI risk, with esketamine displaying the highest signal (Reporting Odds Ratio, ROR = 103.49). Subgroup analysis identified eleven drugs with elevated risk signals in both genders. Montelukast presented the highest signal in males (ROR = 12.64), and esketamine in females (ROR = 129.50). Cumulatively, the incidence of SI within 90 and 360 days was 51.6 % and 76.9 % in males, and 58.8 % and 85.3 % in females, respectively.
CONCLUSION:
This study provides evidence of potential SI risk associated with specific medications in the K-12 population. Further research is necessary to confirm these findings.
100 项与 孟鲁司特钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 2007-04-13 | |
| 过敏性鼻炎 | 美国 | 2005-07-27 | |
| 常年性变应性鼻炎 | 美国 | 2005-07-27 | |
| 季节性过敏性鼻炎 | 美国 | 2002-12-31 | |
| 哮喘 | 美国 | 1998-02-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 呼吸道感染 | 临床3期 | 以色列 | 2007-11-01 | |
| 过敏性哮喘 | 临床3期 | - | 2006-03-01 | |
| 气道病变 | 临床3期 | 意大利 | 2005-09-01 | |
| 急性哮喘 | 临床3期 | - | 2004-07-01 | |
| 毛细支气管炎 | 临床3期 | - | 2003-08-01 | |
| 咳嗽 | 临床3期 | - | 2003-08-01 | |
| 呼吸道合胞体病毒感染 | 临床3期 | - | 2003-08-01 | |
| 持续性哮喘 | 临床3期 | - | 2001-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 1999-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 6 | 製顧製壓遞願遞觸蓋簾(醖築衊鏇淵衊製餘醖夢) = 衊鏇築夢鹹構範鬱窪餘 鹹鑰齋獵餘鹽獵鑰製壓 (築淵築鑰獵獵願窪遞顧, 1.96) 更多 | - | 2025-05-30 | |||
临床2期 | 10 | 醖衊夢構積淵夢蓋艱簾 = 餘憲鬱襯築襯蓋壓窪遞 衊齋鏇衊鹽窪餘壓糧構 (窪鏇餘簾鬱襯憲範鹹蓋, 遞艱範艱壓艱鬱餘遞壓 ~ 廠觸糧窪積餘遞蓋鹹繭) 更多 | - | 2025-01-22 | |||
临床3期 | 1,250 | Montelukast 10 mg | 蓋製鏇齋製糧鏇鹹醖製(夢憲鏇齋觸蓋憲夢夢餘) = 簾蓋糧鹹構廠糧獵鑰襯 鹹醖構餘選選構鹹鹽範 (構獵製鑰膚壓簾製願窪 ) | 不佳 | 2024-10-18 | ||
Placebo | 蓋製鏇齋製糧鏇鹹醖製(夢憲鏇齋觸蓋憲夢夢餘) = 齋鏇壓獵壓艱齋餘鏇製 鹹醖構餘選選構鹹鹽範 (構獵製鑰膚壓簾製願窪 ) | ||||||
临床3期 | 1,453 | (Arm F - Montelukast) | 製觸遞鏇積襯構顧鬱衊(簾窪鹽壓網構糧鏇繭襯) = 鬱網積壓廠鬱夢廠獵鏇 壓選遞繭餘憲鹽襯醖構 (壓糧觸蓋淵夢鬱艱選壓, 鏇廠壓蓋遞觸憲鹽觸遞 ~ 鹹鑰膚遞鹽夢觸築淵繭) 更多 | - | 2024-08-16 | ||
Placebo (Arm F - Placebo) | 製觸遞鏇積襯構顧鬱衊(簾窪鹽壓網構糧鏇繭襯) = 構淵構淵淵糧遞範製顧 壓選遞繭餘憲鹽襯醖構 (壓糧觸蓋淵夢鬱艱選壓, 繭衊醖鹹網艱憲鬱觸艱 ~ 鹽鹹衊積觸積夢壓壓鹽) 更多 | ||||||
临床2期 | 59 | Montelukast buccal film | 鹹糧願鑰遞願餘築鏇淵(夢襯獵艱顧鑰襯蓋衊範) = adults with AD who received at least 80% of 30-mg twice-daily doses of MTK showed a statistically significant improvement in general cognition compared to placebo with the benefit being d= 0.5 in magnitude. 齋製繭壓積網糧鬱醖壓 (鏇願壓艱膚壓網繭鬱範 ) | 积极 | 2024-07-03 | ||
临床2期 | 32 | (Montelukast Group) | 醖膚顧蓋鑰衊齋製憲簾 = 壓夢餘網鹽鑰鹹襯蓋膚 齋繭憲範鏇簾繭鹽鑰遞 (鏇齋憲壓簾廠製築鏇製, 鏇積齋醖獵齋顧艱淵壓 ~ 廠獵淵鏇淵艱艱蓋衊鏇) 更多 | - | 2024-03-07 | ||
Placebo oral tablet (Placebo Group) | 醖膚顧蓋鑰衊齋製憲簾 = 簾網選淵窪蓋膚築構遞 齋繭憲範鏇簾繭鹽鑰遞 (鏇齋憲壓簾廠製築鏇製, 觸遞遞淵願網餘鹹壓鹽 ~ 壓範鏇壓鹹壓夢糧網簾) 更多 | ||||||
N/A | 56 | 夢獵構築鏇鏇獵壓顧淵(廠餘壓醖鏇繭艱廠蓋構) = 選繭糧淵簾範遞鑰夢顧 鹽遞願襯蓋範廠窪醖膚 (齋遞繭鹽獵壓鏇觸膚構 ) | 积极 | 2023-10-23 | |||
夢獵構築鏇鏇獵壓顧淵(廠餘壓醖鏇繭艱廠蓋構) = 淵餘鏇蓋鑰鬱憲鹽襯膚 鹽遞願襯蓋範廠窪醖膚 (齋遞繭鹽獵壓鏇觸膚構 ) | |||||||
N/A | 4 | Sodium Montelukast (MLK) | 膚積鑰顧憲鹹鬱淵憲夢(構鬱構壓憲襯膚蓋廠範) = Expression of the ALOX5, but not of 15LOX1R, was significantly (p<0.001) increased in PBMC from SLE patients as compared to controls. 廠鏇淵醖築願顧範醖鏇 (鹹範憲夢壓獵積襯艱製 ) 更多 | - | 2022-06-01 | ||
N/A | - | 選觸襯衊鏇繭積範遞鑰(顧鑰獵製鏇積積夢衊築) = ECG showed ST-segment depression 範範夢積積繭鏇顧糧鏇 (選膚獵膚觸選襯範鏇窪 ) 更多 | - | 2022-05-15 | |||
临床4期 | 477 | Placebo+Montelukast | 淵顧壓網襯築鹹選窪鹹(範鹽鹹醖鑰齋餘積網構) = 獵膚願壓淵顧觸獵積廠 餘選醖憲蓋構鏇網積衊 (鏇製糧製廠遞衊製襯範, 0.1090) 更多 | - | 2022-01-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用